Is NCT07661329 recruiting in Beverly Hills, CA?

Yes, NCT07661329 is currently recruiting participants at its Beverly Hills, CA location. This primary open angle glaucoma (poag) clinical trial is actively enrolling qualified participants.

Is participation in this Beverly Hills clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Primary Open Angle Glaucoma (POAG) Clinical Trial in Beverly Hills, CA

Q: How do I join the primary open angle glaucoma (poag) clinical trial in Beverly Hills?

To join this clinical trial in Beverly Hills, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Primary Open Angle Glaucoma (POAG) Study in Beverly Hills

This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.

Sponsor: YS Life Science Co., Ltd.

Who Can Participate

Inclusion Criteria

Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.

Male or females aged ≥18 years.

Subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in both eyes

Subjects requiring treatment in both the eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.

Adequate washout period prior to baseline (Day 0) of any ocular hypotensive medications

Baseline (Day 0/hour 0) IOP ≥22 mm Hg and ≤ 34 mm Hg in both eyes, with difference between the IOP in left and right eyes not being more than 5 mm Hg

Subjects' IOP is likely to be controlled with monotherapy.

Baseline best corrected visual acuity equivalent to Snellen acuity of 20/100 or better in each eye, using a logarithmic visual acuity chart.

Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the study participation) practicing any of the following acceptable methods of contraception:

Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.

Intrauterine device (IUD) or intrauterine system (IUS)

Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)

Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)

Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation

Total abstinence; partial abstinence is not acceptable

No history of addiction to any recreational drug or drug dependence or alcohol addiction

Exclusion Criteria

Female subjects with positive pregnancy test or lactating or planning a pregnancy.

Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation or benzalkonium chloride.

Current or history of severe hepatic or renal impairment.

Current or history within 3 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts will be allowed provided that the other inclusion/exclusion criteria are met).

Current corneal abnormalities that would prevent accurate IOP readings with tonometer.

Functionally significant visual field loss as determined by perimetry.

Subjects with corneal grafts.

Subject has contraindication to pupil dilation.

Use at any time prior to baseline of an intraocular corticosteroid implant.

Use of contact lens within 1 week prior to baseline.

Use within 21 days prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.

Use within 21 days prior to baseline of a systemic corticosteroid.

Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid.

Underwent within 3 months prior to baseline any other intraocular surgery (e.g., cataract surgery). Underwent any filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty) within 3 months prior to baseline or refractive surgery at any time.

Subjects with a history of non-responder to bimatoprost monotherapy.

Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.

Severe glaucoma with a cup/disk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion).

Chronic use of any systemic medication that may affect IOP with less than 2 months stable dosing regimen (i.e., sympathomimetic agents, betaadrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)

Central Corneal thickness (CCT) \<480 microns or \>620 microns for study eye.

Known history or presence of any uncontrolled systemic disease

History of recurrent ocular seasonal allergies within past 2 years prior to screening.

Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.

Participation in any clinical study within 30 days before the first dose of the study drug.

Subjects with known cases of active Hepatitis B virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection.

Subjects with aphakia or history of herpes simplex keratitis

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Beverly Hills?

Yes, this clinical trial (NCT07661329) has an active research site in Beverly Hills, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Open Angle Glaucoma (POAG) Treatment Options in Beverly Hills, CA

If you're searching for primary open angle glaucoma (poag) treatment options in Beverly Hills, CA, this clinical trial (NCT07661329) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Beverly Hills research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary open angle glaucoma (poag) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary open angle glaucoma (poag) clinical trials near you to find additional studies recruiting in your area.

Primary Open Angle Glaucoma (POAG) Clinical Trial in Beverly Hills, CA

Expert Care in Beverly Hills

IRB Approved

No-Cost Care

Apply for This Beverly Hills Location

Why Participate?

Simple Process